Galapagos (GLPG) Gets a Buy Rating from Morgan Stanley

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Galapagos (GLPGResearch Report) today and set a price target of $79.00. The company’s shares closed last Friday at $53.54.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.4% and a 52.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Galapagos has an analyst consensus of Moderate Buy, with a price target consensus of $70.00.

See today’s best-performing stocks on TipRanks >>

Based on Galapagos’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $136 million and GAAP net loss of $13.31 million. In comparison, last year the company earned revenue of $114 million and had a net profit of $9.36 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Read More on GLPG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed